Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma [Yahoo! ...
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibi tion in Solid Tumors (U S) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveals growing use of subcutaneous (SC) PD-1 therapies alongside expectations for an eventual shift toward biosimilars across non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC). The study confirms that PD-1/PD-L1 brand preference remains highly tumor-specific. Keytruda (Merck) continues to be strongly preferred in NSCLC and melanoma, driven by established efficacy data and physician familiarity, while treatment patterns in RCC reflect a more balanced split between Keytruda- and Opdivo-based regimens (Bristol Myers Squibb). In RCC, oncologists describe comparatively lower brand equity within the class, with regimen selection driven more by combination strategies, patient risk profiles, and s
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As [Yahoo! Finance]Yahoo! Finance
- Is Merck Stock A Trap At $110? [Forbes]Forbes
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance Canada]Yahoo! Finance Canada
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade [Yahoo! Finance]Yahoo! Finance
- Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings? [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- MRK's page on the SEC website